| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
T0080 (5 µM; 2–6 h) inhibited the activation of primary mouse neutrophils isolated from pMCAO mice, reduced their migration on bEnd.3 endothelial cell monolayers, and maintained the integrity of tight junctions and in vitro viability of bEnd.3 cells [1]. T0080 reduced mtFP-induced apoptosis in human induced pluripotent stem cell-derived neurons and oligodendrocytes co-cultured with microglia [2].
|
|---|---|
| ln Vivo |
T0080 (5 mg/kg; intraperitoneal injection; single dose; 1 or 2 hours after pMCAO) significantly reduced tPA-induced hemorrhagic transformation and neurological deficits in mice, reduced neutrophil brain infiltration, and maintained the integrity of the blood-brain barrier [1]. T0080 (5 mg/kg; intraperitoneal injection; single dose; 3 hours after tMCAO, i.e., during tPA thrombolysis) significantly reduced tPA-induced hemorrhagic transformation and neurological deficits in tMCAO mouse models [1]. T0080 (5 mg/kg; intraperitoneal injection; once daily) reduced clinical symptoms, demyelination, central nervous system immune cell infiltration, and spinal cord inflammation in C57BL/6 EAE mice [2]. T0080 (5 mg/kg; intraperitoneal injection; once daily) reduced clinical symptoms, demyelination, and axonal loss in a secondary progressive NOD-EAE mouse MS model [2]. T0080 (5 mg/kg; intraperitoneal injection; once daily) reduced myelin loss in a copper azole-induced MS demyelination mouse model [2]. T0080 (5 mg/kg; intraperitoneal injection; once daily) reduced microglia expressing human FPR1 in humanized FPR1 transgenic EAE mice [2].
|
| Animal Protocol |
Animal/Disease Models:C57BL/6 mouse ischemic stroke model (male, 8-10 weeks old, photothrombosis-induced middle cerebral artery occlusion model) [1]
Doses: 5 mg/kg (1 hour after pMCAO); 5 mg/kg (2 hours after pMCAO) Route of Administration: Intraperitoneal injection; single dose Experimental Results: Compared with the vector control group, the modified neurological severity score (mNSS) was significantly reduced. Compared with the vector control group, the rotarod test results were significantly improved. Compared with the vector control group, the hemoglobin content and Evans blue extravasation in the ischemic hemisphere were significantly reduced. Compared with the vector control group, the infiltration of Ly6G+ neutrophils in the brain was reduced. Compared with the vector control group, the relative fluorescence intensity of tight junction proteins Claudin-5 and ZO-1 was increased. |
| References |
| Molecular Formula |
C24H22F3N3O3
|
|---|---|
| Molecular Weight |
457.44
|
| CAS # |
2785323-68-2
|
| Appearance |
White to off-white solid
|
| SMILES |
OC1=CC=C(C)C=C1C2=C(C(C3=CC=C(C(F)(F)F)C=C3)N(C4CCOCC4)C5=O)C5=NN2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~218.61 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1861 mL | 10.9304 mL | 21.8608 mL | |
| 5 mM | 0.4372 mL | 2.1861 mL | 4.3722 mL | |
| 10 mM | 0.2186 mL | 1.0930 mL | 2.1861 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
